Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method for reducing the risk of myocardial infarction in a human, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene NPC1 as represented by position 101 of SEQ ID NO:59198 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO:59198 or C at said complement;
b) detecting said G or said C;
c) identifying said human as having an increased risk for myocardial infarction or as being responsive to statin treatment for reducing their risk of myocardial infarction due to the presence of said G or said C; and
d) administering a statin to said human.
2. The method of claim 1 , wherein the method comprises identifying said human as having an increased risk for myocardial infarction.
3. The method of claim 1 , wherein said method comprises preparing a sample from said human that is enriched for a fragment of said nucleic acid that includes said position 101 of SEQ ID NO:59198 or its complement by amplifying said fragment by polymerase chain reaction (PCR).
4. The method of claim 1 , wherein said testing comprises amplifying by polymerase chain reaction (PCR) a fragment of said nucleic acid that includes said position 101 of SEQ ID NO:59198 or its complement to thereby create an amplicon containing said position, and contacting said amplicon with said oligonucleotide.
5. The method of claim 1 , wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO:59198 or its complement that includes said position 101.
6. The method of claim 1 , wherein said oligonucleotide is an allele-specific probe or an allele-specific primer.
7. The method of claim 1 , wherein said oligonucleotide is an allele-specific primer comprising SEQ ID NO:85340.
8. The method of claim 1 , wherein said testing comprises allele-specific amplification, and further wherein said detecting comprises detecting the presence of an amplicon.
9. The method of claim 1 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
10. The method of claim 1 , wherein said human is heterozygous for said G or said C.
11. The method of claim 1 , wherein said human is homozygous for said G or said C.
12. A method for reducing the risk of myocardial infarction in a human, the method comprising:
a) receiving an identification of a human as having an increased risk for myocardial infarction or as being responsive to statin treatment for reducing their risk of myocardial infarction due to a polymorphism in gene NPC1 comprising G at position 101 of SEQ ID NO:59198 or C at its complement; and
b) administering a statin to said human.
13. The method of claim 12 , wherein said human is homozygous for said G or said C.
14. The method of claim 12 , wherein said human is heterozygous for said G or said C.